Related Experiment Videos
Cefotaxime therapy of serious bacterial infection in adults
Abstract:
We evaluated the efficacy, safety, and tolerance of cefotaxime in 35 adults (25 with pleuropulmonary infections, 7 with genitourinary tract infections, and 3 with soft tissue infections). Of these 35 patients, 18 (51.4%) were seriously or critically ill. In vitro susceptibility testing revealed that 90.4% of the pathogens isolated were susceptible to cefotaxime (minimal inhibitory concentration, less than 8 micrograms/ml), 4.8% were intermediately susceptible (minimal inhibitory concentration, 8 to 32 micrograms/ml), and 4.8% were resistant (minimal inhibitory concentration, greater than 32 micrograms/ml). A total of 34 of the 35 patients (97%) were clinically and bacteriologically cured of their infections. Adverse reactions occurred in two patients, but these reactions did not require interruption of therapy.
Insights
Cefotaxime demonstrated high efficacy and safety in treating serious infections. The antibiotic achieved a 97% cure rate with minimal adverse effects, showing its effectiveness against susceptible pathogens.
Area of Science:
- Clinical Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Serious infections pose significant therapeutic challenges.
- Cefotaxime is a third-generation cephalosporin antibiotic with broad-spectrum activity.
Purpose of the Study:
- To evaluate the clinical efficacy, safety, and tolerance of cefotaxime.
- To assess cefotaxime's effectiveness in treating pleuropulmonary, genitourinary, and soft tissue infections.
Main Methods:
- A study involving 35 adult patients with various infections.
- In vitro susceptibility testing of isolated pathogens against cefotaxime.
- Clinical and bacteriological assessment of treatment outcomes.
Main Results:
- 90.4% of isolated pathogens were susceptible to cefotaxime.
- A clinical and bacteriological cure rate of 97% was achieved in 34 out of 35 patients.
- Only two patients experienced adverse reactions, none requiring therapy interruption.
Conclusions:
- Cefotaxime is highly effective and well-tolerated for treating serious bacterial infections.
- The antibiotic exhibits excellent in vitro activity against a majority of tested pathogens.
- Cefotaxime represents a safe and valuable therapeutic option for indicated infections.